Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec 31;9(4):228-230.
doi: 10.2478/jtim-2021-0023. eCollection 2021 Dec 1.

Dawning precision treatment for gastric cancer: The latest biomarkers

Keran Sun  1 , Huifang Lv  1 , BeiBei Chen  1 , Caiyun Nie  1 , Jing Zhao  1 , Saiqi Wang  1 , Jianzheng Wang  1 , Weifeng Xu  1 , Xiaobing Chen  1
Affiliations
Editorial

Dawning precision treatment for gastric cancer: The latest biomarkers

Keran Sun et al. J Transl Int Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marrelli D, Polom K, Pascale V, Vindigni C, Piagnerelli R, De Franco L, et al. Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Ann Surg Oncol 2016; 23: 943-50. - PubMed
    2. Marrelli D, Polom K, Pascale V, Vindigni C, Piagnerelli R, De Franco L. et al. Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Ann Surg Oncol. 2016;23:943–50. - PubMed
    1. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018; 4: e180013. - PMC - PubMed
    2. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M. et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4:e180013. - PMC - PubMed
    1. Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018; 392: 123-33. - PubMed
    2. Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123–33. - PubMed
    1. Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer 2020;23:510-9. - PMC - PubMed
    2. Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC. et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23:510–9. - PMC - PubMed
    1. Liu JB, Jian T, Yue C, Chen D, Chen, W, Bao TT, et al. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus. Anticancer Res 2019; 39: 1689-98. - PubMed
    2. Liu JB, Jian T, Yue C, Chen D, Chen W, Bao TT. et al. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus. Anticancer Res. 2019;39:1689–98. - PubMed

Publication types

LinkOut - more resources